New shoulder implant shows promise in early study

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 18 years of age or older * Patient must be skeletally mature with degenerative disease of the glenohumeral joint where hemi or total shoulder arthroplasty * Meets the Catalyst CSR Shoulder System Indications for Use according to approved labeling Exclusion Criteria * Has a history of open surgery to index shoulder prior to treatment with the Catalyst CSR system? (history of previous arthroscopic surgery allowed) * Has a full thickness rotator cuff tear diagnosed by MFI or marked posterior glenoid wear * Patient is unwilling or unable to comply with the post-operative care instructions, attend follow visits per the study schedule and complete the study assessments (i.e., Pros) * The patient is a non-English speaker * In the opinion of the investigator, is it not in the patient's best interest to participate in this study * Local or systemic infection, or osteomyelitis of the proximal humerus or scapula; if a systemic infection or a secondary remote infection is suspected or confirmed, joint replacement surgery should be delayed until infection is resolved * Inadequate or malformed bone that precludes adequate support of fixation of the prosthesis * Osteoporosis * Neuromuscular disorders that do not allow control of the joint * Chronic instability, chronic dislocation or deficient soft tissues and other support structures (e.g., brachial plexus or deltoid muscles) * Vascular insufficiency * Subject's age, weight or activity level cause the surgeon to expect early failure of the system * The patient is unwilling to comply or unable to comply with the post-operative care instructions * Alcohol, drug, substance abuse or other conditions that would affect or impair the patient from complying with post-operative instructions * Patients with known sensitivity to Co-Cr-Mo alloys typically used prosthetic devices * Any disease that could adversely affect the function or expected longevity of the implants (e.g., metabolic disorders)